Report
Pharma Mar : Q1 earnings in line
>Oncology gains momentum - Sales grew +12% y-o-y in Q1 2024 (vs -20% in Q4 and -9% in Q3). Biopharma sales increased +25% y-o-y in Q1 2024 (compared to -32% in Q4 and -27% in Q3) namely owing to higher revenues from Zepzelca and, to a lesser extent, also higher raw material and ‘early access’ sales. Royalties posted a +14% y-o-y increase (vs -6% in Q4 and+20% in Q3) while the more erratic licence revenues declined -8% which nonetheless implies a material sequential im...
Underlying
Pharma Mar SA
Provider
Oddo BHF
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Juan Ros-Padilla
Other Reports on these Companies
Other Reports from Oddo BHF
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.